loading page

Single-drug vinorelbine as a salvage re-induction regimen for 4 consecutive pediatric patients with relapsed anaplastic large-cell lymphoma in a single children's institution
  • +3
  • Qing Yuan,
  • Qiao He,
  • Qiang Mi,
  • Min-Zhi Yin,
  • Yali Han,
  • Yijin Gao
Qing Yuan
Shanghai Childrens Medical Center Affiliated to Shanghai Jiaotong University School of Medicine
Author Profile
Qiao He
Shanghai Childrens Medical Center Affiliated to Shanghai Jiaotong University School of Medicine
Author Profile
Qiang Mi
Shanghai Childrens Medical Center Affiliated to Shanghai Jiaotong University School of Medicine
Author Profile
Min-Zhi Yin
Shanghai Childrens Medical Center Affiliated to Shanghai Jiaotong University School of Medicine
Author Profile
Yali Han
Shanghai Childrens Medical Center Affiliated to Shanghai Jiaotong University School of Medicine
Author Profile
Yijin Gao
Shanghai Childrens Medical Center Affiliated to Shanghai Jiaotong University School of Medicine
Author Profile

Abstract

Approximately 20–40% of pediatric patients with anaplastic large-cell lymphoma (ALCL) develop recurrent disease. Here, we report a pilot experience using single-drug weekly vinorelbine (25 mg/m2/wk) as a salvage re-induction regimen in 4 consecutive pediatric patients with relapsed ALCL. All 4 patients achieved complete remission after 2 cycles of weekly vinorelbine and were disease-free alive at last evaluation. The main toxicity was hematologic. Only one week of vinorelbine administration was withheld for a grade 4 neutropenia in one patient. The results suggest that weekly vinorelbine has good efficacy and safety in the treatment of relapsed pediatric ALCL.